Tiziana (LON:TILS, NASDAQ:TLSA) is advancing its lead immunotherapy Foralumab, a fully-human anti-CD3 monoclonal antibody (mAb) being developed for oral and nasal routes of administration, providing novel approaches in treating severe inflammatory and autoimmune disease. Top-line data from a recent
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Tiziana Life Sciences: Advancing the therapeutic pipeline
- Published:
15 Apr 2021 -
Author:
Emma Ulker -
Pages:
4
Tiziana (LON:TILS, NASDAQ:TLSA) is advancing its lead immunotherapy Foralumab, a fully-human anti-CD3 monoclonal antibody (mAb) being developed for oral and nasal routes of administration, providing novel approaches in treating severe inflammatory and autoimmune disease. Top-line data from a recent